CAMBRIDGE, Mass. - TelAve -- In response to the recent emergency medical evacuation from the International Space Station (ISS), Diopter Labs today released mission-readiness data for Bioshare, a dissolvable ocular therapy designed to provide regenerative care in zero-gravity and high-radiation environments.

The Crew-11 evacuation—the first such emergency in the station's 25-year history—has exposed a critical vulnerability: the lack of autonomous, shelf-stable regenerative tools for ocular injuries. Bioshare addresses this by combining the biological power of human amnion with a structural collagen matrix in a self-dissolving lens.

More on TelAve News

• Aleen Inc. (C S E: ALEN.U) Advances Digital Wellness Vision with Streamlined Platform Navigation and Long-Term Growth Strategy
• RimbaMindaAI Officially Launches Version 3.0 Following Strategic Breakthrough in Malaysian Market Analysis
• Fed Rate Pause & Dow 50k: Irfan Zuyrel on Liquidity Shifts, Crypto Volatility, and the ASEAN Opportunity
• 20/20 Institute Launches Updated Vision Correction Procedures Page for Denver & Colorado Springs
• OneVizion Announces Next Phase of Growth as Brad Kitchens Joins Board of Directors

The Regenerative Synergy of Amnion and Collagen

Unlike standard synthetic "bandage" lenses, Bioshare utilizes the natural healing properties of its core components to rebuild damaged ocular tissue:

• Human Amnion: Naturally rich in growth factors (EGF, TGF-beta) and anti-inflammatory cytokines, the amnion layer suppresses scarring and "resets" the healing process in chronic or acute wounds. It acts as a biological substrate, facilitating the rapid migration of epithelial cells to close corneal defects.
• Collagen Matrix: The integrated collagen serves as a 3D structural scaffold. In microgravity, where cellular growth is often delayed, this scaffold provides the necessary architecture for new tissue to take hold, mimicking the eye's native extracellular matrix.

"In a remote environment like the ISS or a future Mars mission, you cannot wait for a surgeon or a refrigerated delivery of biologics," said Chris Adams, CEO at Diopter Labs. "Bioshare is stable at room temperature and leverages the body's own regenerative pathways. By providing both the 'blueprints' (Amnion) and the 'scaffolding' (Collagen), we can stabilize and heal sight-threatening injuries autonomously."

More on TelAve News

• New Children's Picture Book "Diwa of Mount Luntian" Focuses on Calm, Culture, and Connection for Today's Families
• Actor, Spokesperson Rio Rocket Featured in "Switch to AT&T" Campaign Showing How Customers Can BYOD and Keep Their Number
• The World's No.1 Superstar® Brings Disco Fever Back With New Global Single and Video "Disco Dancing"
• Boston Industrial Solutions' Natron® 512N Series UV LED Ink Achieves BPA Certification, Advancing Safe and Sustainable Digital Printing
• Joan Nissen promoted to Century Fasteners Corp. – General Manager, Aerospace & Government Sales

Built for the "Space Medicine" Kit

Bioshare is engineered to be applied like a standard contact lens, requiring no specialized training or surgical equipment. Its ability to remain stable without refrigeration makes it a vital candidate for the limited-resource medical bays of the next generation of spacecraft.

About Diopter Labs

Diopter Labs (http://diopterlabs.com) is a biotechnology leader in ocular regenerative medicine, focusing on the development of "clinic-in-a-lens" technologies that bridge the gap between emergency trauma and long-term healing.